LONG-TERM EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO BDMARDS: RESULTS FROM RA-BEYOND UP TO 6.9-YEARS OF TREATMENT

被引：0
|
作者：
Caporali, Roberto [1 ]
Aletaha, Daniel [2 ]
Sanmarti, Raimon [3 ,4 ]
Takeuchi, Tsutomu [5 ]
Mo, Daojun [6 ]
Haladyj, Ewa [6 ]
Zaremba-Pechmann, Liliana [7 ]
Taylor, Peter C. [8 ]
Pile, Kevin [9 ]
机构：
[1] Univ Milan, Dept Clin Sci & Community Hlth, Res Ctr Adult & Pediat Rheumat Dis, Milan, Italy
[2] Med Univ Vienna, Div Rheumatol, Dept Med 3, Vienna, Austria
[3] Hosp Clin Barcelona, Dept Rheumatol, Barcelona, Spain
[4] IDIBAPS, Barcelona, Spain
[5] Keio Univ, Div Rheumatol, Dept Internal Med, Sch Med, Tokyo, Japan
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] HaaPACS GmbH, Schriesheim, Germany
[8] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford, England
[9] Western Sydney Univ, Sydney, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2023年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
ARA-P64
引用
收藏
页码：35 / 35
页数：1
相关论文
共 50 条
  • [21] Efficacy of Long-term Treatment with Baricitinib 2 Mg in Patients with Active Rheumatoid Arthritis
    Wells, Alvin
    Jia, Bochao
    Xie, Li
    Valenzuela, Guillermo
    Keystone, Edward C.
    Li, Zhanguo
    Quebe, Amanda
    Griffing, Kirstin
    Otawa, Susan
    Haraoui, Boulos
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [22] TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: LONG-TERM EFFICACY FOR UP TO 3.5 YEARS
    Smolen, J. S.
    Gomez-Reino, J. J.
    Davies, C.
    Alecock, E.
    Rubbert-Roth, A.
    Emery, P.
    [J]. RHEUMATOLOGY, 2010, 49 : I110 - I111
  • [23] Tocilizumab (TCZ) Long-Term Efficacy in Rheumatoid Arthritis (RA) Patients (pts) Treated up to 3.7 Years
    Khraishi, Majed
    Haraoui, Boulos
    Alten, Rieke
    Gomez-Reino, Juan
    Rizzo, Warren
    Schechtman, Joy
    Kahan, Andre
    Vernon, Emma
    Taylor, Monet
    Smolen, Joseph
    [J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 (06) : 1164 - 1164
  • [24] Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks
    Burmester, Gerd
    Van den Bosch, Filip
    Bessette, Louis
    Kivitz, Alan
    Li, Yihan
    Friedman, Alan
    Pangan, Aileen
    Camp, Heidi
    Kremer, Joel
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [25] P134 Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with RA: results from RA-BEYOND
    van der Heijde, Desiree M. F. M.
    Kartman, Cynthia E.
    Xie, Li
    Beattie, Scott
    Schlichting, Douglas E.
    Durez, Patrick
    Tanaka, Yoshiya
    Fleischmann, Roy
    [J]. RHEUMATOLOGY, 2021, 60
  • [26] Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study
    Li, Z.
    Hu, J.
    Bao, C.
    Li, X.
    Li, X.
    Xu, J.
    Spindler, A. J.
    Zhang, X.
    Xu, J.
    He, D.
    Li, Z.
    Wang, G.
    Yang, Y.
    Wu, H.
    Ji, F.
    Tao, H.
    Zhan, L.
    Bai, F.
    Rooney, T. P.
    Zerbini, C. A. F.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (04) : 732 - 741
  • [27] Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
    Taylor, Peter C.
    Takeuchi, Tsutomu
    Burmester, Gerd R.
    Durez, Patrick
    Smolen, Josef S.
    Deberdt, Walter
    Issa, Maher
    Terres, Jorge Ross
    Bello, Natalia
    Winthrop, Kevin L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (03) : 335 - 343
  • [28] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CSDMARDS: RESULTS AT 60 WEEKS FROM THE SELECT-NEXT STUDY
    Burmester, Gerd Ruediger
    van den Bosch, Filip
    Bessette, Louis
    Kivitz, Alan
    Li Yihan
    Friedman, Alan
    Pangan, Aileen
    Camp, Heidi
    Kremer, Joel
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 735 - 736
  • [29] LONG-TERM EFFICACY OF TOCILIZUMAB UP TO 3.5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN INTERIM ANALYSIS OF LONG-TERM EXTENSION STUDIES
    Calvo, A.
    Sid, D.
    Saavedra, M.
    Kissel, K.
    Alecock, E.
    Smolen, J.
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (03) : S34 - S34
  • [30] Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND
    van Vollenhoven, Ronald F.
    Hall, Stephen
    Wells, Alvin F.
    Meerwein, Sebastian
    Song, Yanna
    Tanjinatus, Oishi
    Fleischmann, Roy
    [J]. RMD OPEN, 2024, 10 (03):
12345